Filing Details
- Accession Number:
- 0001415889-25-003165
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-02-05 20:00:05
- Reporting Period:
- 2025-02-03
- Filing Date:
- 2025-02-05
- Accepted Time:
- 2025-02-05 20:00:05
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1817713 | Janux Therapeutics Inc. | JANX | Pharmaceutical Preparations (2834) | 822289112 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1864159 | Hollman Andrew Meyer | C/O Janux Therapeutics, Inc. 10955 Vista Sorrento Parkway, Suite 200 San Diego CA 92130 | Chief Business Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2025-02-03 | 3,334 | $4.21 | 85,473 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2025-02-03 | 2,418 | $42.08 | 83,055 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2025-02-03 | 816 | $42.77 | 82,239 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2025-02-03 | 100 | $43.60 | 82,139 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2025-02-03 | 3,334 | $0.00 | 3,334 | $4.21 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 97,333 | 2031-03-09 | No | 4 | M | Direct |
Footnotes
- The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2024.
- The weighted average sale price for the transaction reported was $42.0756 and the range of prices were between $41.55 and $42.40. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- The weighted average sale price for the transaction reported was $42.7703 and the range of prices were between $42.56 and $43.00. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- Immediately exercisable.
Billionaire Hedge Funds
